CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2004 (2013.01); A61K 9/4841 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4995 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01)] | 24 Claims |
1. A method of treating mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), or chronic graft versus host disease (cGVHD) in a patient in need thereof with an anti-neoplastic drug, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
a. discontinuing the strong CYP3A4 inhibitor treatment;
b. delaying administering, for at least about 3 days after discontinuing the strong CYP3A4 inhibitor treatment, a dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
c. administering the dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
wherein the strong CYP3A4 inhibitor is posaconazole.
|